PERSPECTIVE ОF USE ОF AGONISTS OF ADENOSINE AND OPIOID RECEPTORS FOR PREVENTION OF REPERFUSION DAMAGES OF HEART. ANALYSIS OF EXPERIMENTAL AND CLINICAL DATA

Cover Page
  • Authors: Maslov L.N.1, Mrochek A.G.2, Khaliulin I.G.3, Portnichenko A.G.4, Chausskaya E.5, Krylatov A.V.6, Naryzhnaya N.V.6, Gorbunov A.S.6, Tsibul'nikov S.Y.6
  • Affiliations:
    1. Research Institute for Cardiology, Tomsk
    2. Republic Scientific-Practical Center «Cardiology», Minsk
    3. University of Bristol
    4. A.A. Bogomoletz Institute of Physiology, Kiev
    5. The Hebrew University of Jerusalem
    6. Research Institute for Cardiology, Tomsk, Russian Federation
  • Issue: Vol 69, No 5-6 (2014)
  • Pages: 5-13
  • Section: РATHOPHYSIOLOGY: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/422
  • DOI: https://doi.org/10.15690/vramn.v69i5-6.1037
  • Cite item

Abstract


In Russia inhospital lethality after acute myocardial infarction is 16,5–16,7%. The part of patients perishes even after recanalisation of infarctrelated coronary artery as a result of reperfusion cardiac injury. Experimental data indicate that adenosine receptor agonists and opioids can prevent reperfusion damages of heart that is mimic postconditioning phenomena. Data of clinical observation show that adenosine during intravenous infusion or intracoronary administration during thrombolysis or percutaneous coronary intervention exert infarct reducing effect and eliminate manifestation of «no-reflow» phenomenon. Clinical data indicate that morphine is able to prevent cardiac reperfusion injury in human. Thus, analysis of published data testifies that adenosine and opioid receptor agonists can be prototype for development of drugs for prophylaxis of reperfusion heart injury.


About the authors

L. N. Maslov

Research Institute for Cardiology, Tomsk

Author for correspondence.
Email: Maslov@cardio-tomsk.ru

Russian Federation PhD, professor, Head of the Laboratory of Experimental Cardiology of Research Institute of Cardiology

A. G. Mrochek

Republic Scientific-Practical Center «Cardiology», Minsk

Email: a.mrochek@mail.by

Belarus PhD, professor, academician of the National Academy of Sciences of Belarus, Director of the Republic Research Centre “Cardiology”

I. G. Khaliulin

University of Bristol

Email: I.Khaliulin@bristol.ac.uk

United Kingdom MD, research scientist of the Laboratory of Biochemistry of Bristol University

A. G. Portnichenko

A.A. Bogomoletz Institute of Physiology, Kiev

Email: port@serv.biph.kiev.ua

Ukraine MD, senior research scientist of the Department of General and Molecular Pathophysiology of A.A. Bogomol'ts Institute of Physiology

Eva Chausskaya

The Hebrew University of Jerusalem

Email: evchik@inbox.ru

Israel MD, research scientist at the Department of Developmental Biology and Cancer Research, Faculty of Medicine of the Hebrew University of Jerusalem

A. V. Krylatov

Research Institute for Cardiology, Tomsk, Russian Federation

Email: Maslov@cardio-tomsk.ru

Russian Federation

MD, senior research scientist of the Laboratory of Experimental Cardiology of Research Institute of Cardiology. Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74

N. V. Naryzhnaya

Research Institute for Cardiology, Tomsk, Russian Federation

Email: natalynar@yandex.ru

Russian Federation kandidat meditsinskikh nauk, starshii nauchnyi sotrudnik laboratorii ekspe-rimental’noi kardiologii NII kardiologii
Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74

A. S. Gorbunov

Research Institute for Cardiology, Tomsk, Russian Federation

Email: barabator@sibmail.com

Russian Federation

kandidat meditsinskikh nauk, mladshii nauchnyi sotrudnik laboratorii eksperimental’noi kardiologii NII kardiologii
Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74

S. Yu. Tsibul'nikov

Research Institute for Cardiology, Tomsk, Russian Federation

Email: seregka2010@hotmail.com

Russian Federation kandidat meditsinskikh nauk, mladshii nauchnyi sotrudnik laboratorii eksperimental’noi kardiologii NII kardiologii
Address: 111, Kievskaya Street, Tomsk, RF, 634012, tel.: +7 (3822) 26-21-74

References

  1. Nikolaeva N.V., Fedorov V.V., Privalova V.Yu., Gal'yanov A.A. Kardiologiya = Cardiology. 1997; 37(3): 73.
  2. Shal'nova S.A., Deev A.D. Ter. arkhiv = Therapeutic archive. 2011; 83(1): 7–12.
  3. Oganov R.G., Pogosova G.V. Kardiologiya = Cardiology. 2007; 47(12): 4–9.
  4. Chazov E.I. Ter. arkhiv = Therapeutic archive. 2008; 80(8): 11–16.
  5. Gafarov V.V., Gafarova A.V. Ter. arkhiv = Therapeutic archive. 2011; 83(1): 38–45.
  6. Oganov R.G., Maslennikova G.Ya. Kardiologiya = Cardiology. 2007; 47(1): 4–7.
  7. Gafarov V.V. Ter. arkhiv = Therapeutic archive. 2000; 72 (1): 15–21.
  8. Sidorenkov O., Nilssen O., Nieboer E., Kleshchinov N., Grjibovski A.M. Premature cardiovascular mortality and alcohol consumption before death in Arkhangelsk, Russia: an analysis of a consecutive series of forensic autopsies. Int. J. Epidemiol. 2011; 40 (6): 1519–1529.
  9. Yavelov I.S., Gratsianskii N.A. Kardiologiya = Cardiology. 2004; 44(4): 4–13.
  10. Simes R.J., O’Connell R.L., Aylward P.E., Varshavsky S., Diaz R., Wilcox R.G., Armstrong P.W., Granger C.B., French J.K., Van de Werf F., Marschner I.C., Califf R., White H.D.; HERO-2 Investigators. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Am. Heart J. 2010; 159 (6): 988–997.
  11. Erlikh A.D., Gratsianskii N.A. Kardiologiya = Cardiology. 2009; 49(7–8): 4–12.
  12. Maslov L.N. Angiol. sosud. khirurgiya = Angiology and vascular surgery. 2007; 13(4): 9–19.
  13. Gafarov V.V., Blaginina M.Yu. Kardiologiya = Cardiology. 2005; 45(8): 48–50.
  14. Gafarov V.V., Gafarova A.V., Blaginina M.Yu. Kardiologiya = Cardiology. 2005; 45(8): 48–50.
  15. Antman E.M., Morrow D.A., McCabe C.H., Murphy S.A., Ruda M., Sadowski Z., Budaj A., Lоpez-Sendоn J.L., Guneri S., Jiang F., White H.D., Fox K.A., Braunwald E.; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 2006; 354 (14): 1477–1488.
  16. Panova E.I. Klin. med = Clinical medicine. 2008; 86(12): 19–23.
  17. Syrkin A.S. Infarkt miokarda [Myocardial Infarction]. Moscow, MIA, 2003. 466 p.
  18. Curtis M.J., Macleod B.A., Walker M.J.A. Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J. Mol. Cell. Cardiol. 1987; 19 (4): 399–419.
  19. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74 (5): 1124–1136.
  20. Alker K.J., Bellows S.D., Kloner R.A. Stuttering reperfusion of ischemic myocardium does not exacerbate myocardial infarction: evidence against lethal cell reperfusion injury in the rabbit. J. Thromb. Thrombolysis. 1996; 3 (3): 185–188.
  21. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2003; 285 (2): 579–588.
  22. Jordan J.E., Zhao Z.Q., Sato H., Taft S., Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. 1997; 280 (1): 301–309.
  23. Philipp S., Yang X.M., Cui L., Davis A.M., Downey J.M., Cohen M.V. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc. Res. 2006; 70 (2): 308–314.
  24. Yang Z., Day Y.J., Toufektsian M.C., Ramos S.I., Marshall M., Wang X.Q., French B.A., Linden J. Infarct-sparing effect of A2Aadenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 2005; 111 (17): 2190–2197.
  25. Yang Z., Day Y.J., Toufektsian M.C., Xu Y., Ramos S.I., Marshall M.A., French B.A., Linden J. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006; 114 (19): 2056–2064.
  26. Garratt K.N., Holmes D.R., Molina-Viamonte V., Reeder G.S., Hodge D.O., Bailey K.R., Lobl J.K., Laudon D.A., Gibbons R.J. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am. Heart J. 1998; 136 (2): 196–204.
  27. Cohen M.V., Downey J.M. Adenosine: trigger and mediator of cardioprotection. Basic Res. Cardiol. 2008; 103 (3): 203–215.
  28. Klabunde R.E. Dipyridamole inhibition of adenosine metabolism in human blood. Eur. J. Pharmacol. 1983; 93(1–2): 21–26.
  29. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., Eisenberg P.R., Bolli R., Casas A.C., Molina-Viamonte V., Orlandi C., Blevins R., Gibbons R.J., Califf R.M., Granger C.B. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of Adenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 1999; 34 (6): 1711–1720.
  30. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., Alexander R.W. AMISTAD-II Investigators. A randomized, double-blinded, placebocontrolled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. 2005; 45 (11): 1775–1780.
  31. Micari A., Belcik T.A., Balcells E.A., Powers E., Wei K., Kaul S., Lindner J.R. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am. J. Cardiol. 2005; 96 (10): 1410–1415.
  32. Kloner R.A., Forman M.B., Gibbons R.J., Ross A.M., Alexander R.W., Stone G.W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur. Heart J. 2006; 27 (20): 2400–2405.
  33. Sakuma T., Motoda C., Tokuyama T., Oka T., Tamekiyo H., Okada T., Otsuka M., Okimoto T., Toyofuku M., Hirao H., Muraoka Y., Ueda H., Masaoka Y., Hayashi Y. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int. J. Cardiol. 2010; 140 (2): 200–209.
  34. North R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002; 82 (4): 1013–1067.
  35. Wang J., Chen Y.D., Zhi G., Xu Y., Chen L., Liu H.B., Zhou X., Tian F. Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin. Exp. Pharmacol. Physiol. 2012; 39 (3): 247–252.
  36. Marzilli M., Orsini E., Marraccini P., Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000; 101 (18): 2154–2159.
  37. Claeys M.J., Bosmans J., De Ceuninck M., Beunis A., Vergauwen W., Vorlat A., Vrints C.J. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am. J. Cardiol. 2004; 94 (1): 9–13.
  38. Vijayalakshmi K., Whittaker V.J., Kunadian B., Graham J., Wright R.A., Hall J.A., Sutton A., de Belder M.A. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006; 92 (9): 1278–1284.
  39. Parikh K.H., Chag M.C., Shah K.J. Shah U.G., Baxi H.A.,
  40. Chandarana A.H., Naik A.M., Shah J.N., Shah H.D., Goyal R.K. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can. J. Physiol. Pharmacol. 2007; 85 (3–4): 476–482.
  41. Stoel M.G., Marques K.M., de Cock C.C., Bronzwaer J.G., von Birgelen C., Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebocontrolled pilot study. Catheter Cardiovasc. Interv. 2008; 71 (3): 283–289.
  42. Tian F., Chen Y.D., Lu S.Z., Song X.T., Yuan F., Fang F., Li Z.A. Intracoronary adenosine improves myocardial perfusion in late reperfused myocardial infarction. Chin. Med. J. 2008; 121 (3): 195–199.
  43. Grygier M., Araszkiewicz A., Lesiak M., Janus M., Kowal J., Skorupski W., Pyda M., Mitkowski P., Grajek S. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Cardiol. 2011; 107 (8): 1131–1135.
  44. Niccoli G., Rigattieri S., De Vita M.R., Valgimigli M., Corvo P., Fabbiocchi F., Romagnoli E., De Caterina A.R., La Torre G., Lo Schiavo P., Tarantino F., Ferrari R., Tomai F., Olivares P., Cosentino N., D’Amario D., Leone A.M., Porto I., Burzotta F., Trani C., Crea F. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013; 6 (6): 580–589.
  45. Quintana M., Hjemdahl P., Sollevi A., Valgimigli M., Corvo P., Fabbiocchi F., Romagnoli E., De Caterina A.R., La Torre G., Lo Schiavo P., Tarantino F., Ferrari R., Tomai F., Olivares P., Cosentino N., D’Amario D., Leone A.M., Porto I., Burzotta F., Trani C., Crea F. ATTACC investigators. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur. J. Clin. Pharmacol. 2003; 59 (1): 1–9.
  46. Fokkema M.L., Vlaar P.J., Vogelzang M., Gu Y.L., Kampinga M.A., de Smet B.J., Jessurun G.A., Anthonio R.L., van den Heuvel A.F., Tan E.S., Zijlstra F. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ. Cardiovasc. Interv. 2009; 2 (4): 323–329.
  47. Peart J.N., Gross E.R., Reichelt M.E., Hsu A., Headrick J.P., Gross G.J. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res. Cardiol. 2008; 103 (5): 454–463.
  48. Bolli R., Triana J.F., Jeroudi M.O. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular «stunning». Circ. Res. 1990; 67 (2): 332–343.
  49. Desmet W., Bogaert J., Dubois C., Sinnaeve P., Adriaenssens T., Pappas C., Ganame J., Dymarkowski S., Janssens S., Belmans A., Van de Werf F. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur. Heart J. 2011; 32 (7): 867–877.
  50. Kopecky S.L., Aviles R.J., Bell M.R., Lobl J.K., Tipping D., Frommell G., Ramsey K., Holland A.E., Midei M., Jain A.,
  51. Kellett M., Gibbons R.J. AmP579 Delivery for Myocardial Infarction REduction study. A randomized, double-blinded, placebocontrolled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am. Heart J. 2003; 146 (1): 146–152.
  52. Smits G.J., McVey M., Cox B.F., Lobl J.K., Tipping D., Frommell G., Ramsey K., Holland A.E., Midei M., Jain A., Kellett M., Gibbons R.J. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J. Pharmacol. Exp. Ther. 1998; 286 (2): 611–618.
  53. Gross E.R., Hsu A.K., Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. 2004; 94 (7): 960–966.
  54. Chang W.L., Lee S.S., Su M.J. Attenuation of post-ischemia reperfusion injury by thaliporphine and morphine in rat hearts. J. Biomed. Sci. 2005; 12 (4): 611–619.
  55. Gross E.R., Hsu A.K., Gross G.J. Diabetes abolishes morphineinduced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3b. Diabetes. 2007; 56 (1): 127–136.
  56. Gross E.R., Hsu A.K., Gross G.J. GSK3b inhibition and KATP channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res. Cardiol. 2007; 102 (4): 341–349.
  57. Tsutsumi Y.M., Yokoyama T., Horikawa Y., Roth D.M., Patel H.H. Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization. Life Sci. 2007; 81 (15): 1223–1227.
  58. Forster K., Kuno A., Solenkova N., Felix S.B., Krieg T. The d-opioid receptor agonist DADLE at reperfusion protects the heart through activation of pro-survival kinases via EGF receptor transactivation. Am. J. Physiol. Heart Circ. Physiol. 2007; 293 (3): 1604–1608.
  59. Chen Z., Li T., Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J. Surg. Res. 2008; 145 (2): 287–294.
  60. Jang Y., Xi J., Wang H., Mueller R.A., Norfleet E.A., Xu Z. Postconditioning prevents reperfusion injury by activating δ-opioid receptors. Anesthesiology. 2008; 108 (2): 243–250.
  61. Kim J.H., Chun K.J., Park Y.H., Kim J., Kim J.S., Jang Y.H., Lee M.Y., Park J.H. Morphine-induced postconditioning modulates mitochondrial permeability transition pore opening via delta-1 opioid receptors activation in isolated rat hearts. Korean J. Anesthesiol. 2011; 61 (1): 69–74.
  62. Gong Z.X., Ran K., Chang Y.T., Xu J.M. Effect of morphine postconditioning on myocardial ischemia-reperfusion injury in rabbits. J. Zhejiang Univ. Med. Sci. 2009; 38 (5): 521–524.
  63. Mourouzis I., Saranteas T., Perimenis P., Tesseromatis C., Kostopanagiotou G., Pantos C., Cokkinos D.V. Morphine
  64. administration at reperfusion fails to improve postischaemic cardiac function but limits myocardial injury probably via heat-shock protein 27 phosphorylation. Eur. J. Anaesthesiol. 2009; 26 (7): 572–581.
  65. Huhn R., Heinen A., Weber N.C., Schlack W., Preckel B., Hollmann M.W. Ischaemic and morphine-induced post-conditioning: impact of mKCa channels. Brit. J. Anaesth. 2010; 105 (5): 589–595.
  66. Fuardo M., Lemoine S., Lo Coco C., Hanouz J.L., Massetti M. [D-Ala2,D-Leu5]-enkephalin (DADLE) and morphine-induced postconditioning by inhibition of mitochondrial permeability transition pore, in human myocardium. Exp. Biol. Med. (Maywood). 2013; 238 (4): 426–432.
  67. Zhang R., Shen L., Xie Y., Gen L., Li X., Ji Q. Effect of morphineinduced postconditioning in corrections of tetralogy of Fallot. J. Cardiothorac. Surg. 2013; 8: 76.
  68. Metelitsa V.I. Spravochnik po klinicheskoi farmakologii serdechno-sosudistykh lekarstvennykh sredstv [Guide in Clinical Pharmacology of Cardiovascular Medicines]. Moscow, BINOM; St. Petersburg, Nevskii Dialekt, 2002. 926 p.

Statistics

Views

Abstract - 314

PDF (Russian) - 397

Cited-By


PlumX

Dimensions

Comments on this article

Comments on this article

View all comments


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies